Services and products for clinical and preclinical research
Stem cell and drug discovery scientists around the world use our solutions to translate their research into therapies.
Service Areas
Blog
Modeling Fibrosis Progression Ex Vivo: Opportunities for Anti-Fibrotic Drug Screening
Explore the benefits of ex vivo human tissue models for fibrosis research and anti-fibrotic drug screening, offering a more accurate alternative to conventional preclinical methods.
15 January 2026
OpenCRISPR-1: The First AI-Designed CRISPR Editor for High-Precision Gene & Cell Therapy
Discover OpenCRISPR-1 — the first fully AI-designed CRISPR–Cas editor. Built by generative large language model, it enables high-efficiency, high-specificity genome and base editing in human cells. Ideal for cell therapy, stem-cell research, and advanced gene-editing workflows.
16 December 2025
Enhancing Experimental Precision with the Alvetex® Advanced Culture System
Discover how Alvetex® Advanced enhances experimental precision with its flexible and functional 3D culture system for creating biologically accurate human skin models.
04 December 2025
iPSC-, MSC- and iMSC-Derived Exosome Therapeutics: The Cell-Free Future of Regenerative Medicine
Explore the future of regenerative medicine with iPSC-, MSC-, and iMSC-derived exosome therapeutics, focusing on their advantages, challenges, and clinical potential.
19 November 2025
Upcoming Events
Conferences we will be attending, and webinars hosted by us
Come and meet us on 9-12 February 2026 / San Diego, California, USA.
9-12 February 2026
Come and meet us at ELRIG Cell and Gene Therapy conference, 9-10 March 2026
9-10 March 2026
Come and meet us at the Advanced Therapies Week, London UK / 17-18 March 2026
17-18 March 2026
Come and meet us at the AACR Annual Meeting 2026 / 17-22 April / San Diego, USA
17-22 April 2026
Corporate News
REPROCELL announces the launch of new hypoimmune hiPSC lines using advanced gene-editing technologies, enhancing precision and efficiency in regenerative medicine and research applications.
07 November 2025
REPROCELL USA Receives Funding from the Maryland Stem Cell Research Fund (MSCRF)
REPROCELL USA receives Maryland Stem Cell Research Fund grant to develop GMP-grade CDMO and iMSC capabilities, enhancing their regenerative medicine and stem cell therapy manufacturing infrastructure.
22 October 2025
REPROCELL Launches Next-Generation System for 3D Bioengineered Tissues
REPROCELL launches Alvetex® Advanced, enhancing 3D cell culture and bioengineered tissue models with improved flexibility and assay compatibility for pharmaceuticals, cosmetics, and medical device testing.
21 October 2025









